Prothena Plc Company Insiders
PRTA Stock | USD 21.16 0.59 2.87% |
Prothena Plc's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Prothena plc suggests that vertually all insiders are panicking. Prothena Plc employs about 173 people. The company is managed by 28 executives with a total tenure of roughly 157 years, averaging almost 5.0 years of service per executive, having 6.18 employees per reported executive.
Dale Schenk CEO CEO and President and Director |
Lars Ekman Chairman Independent Chairman of the Board |
Prothena Plc's Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-01-24 | Karin L. Walker | Disposed 5000 @ 34 | View | ||
2023-12-20 | Karin L. Walker | Disposed 5000 @ 37.19 | View | ||
2023-11-30 | Karin L. Walker | Disposed 5000 @ 34 | View | ||
2023-10-25 | Karin L. Walker | Disposed 5000 @ 41.04 | View | ||
2023-10-11 | Brandon S. Smith | Disposed 4000 @ 46.75 | View | ||
2023-10-04 | Carol D. Karp | Disposed 5000 @ 46.62 | View | ||
2023-09-27 | Michael J. Malecek | Disposed 5000 @ 47.38 | View | ||
2023-09-19 | Karin L. Walker | Disposed 5000 @ 52.36 | View | ||
2023-09-13 | Hideki Garren | Disposed 2000 @ 55.48 | View | ||
2023-09-06 | Carol D. Karp | Disposed 5000 @ 54.76 | View | ||
2023-08-30 | Michael J. Malecek | Disposed 5000 @ 55.01 | View | ||
2023-08-18 | Karin L. Walker | Disposed 5000 @ 57.18 | View | ||
2023-08-16 | Hideki Garren | Disposed 2000 @ 58.74 | View | ||
2023-08-02 | Wagner M. Zago | Disposed 4000 @ 67.05 | View | ||
2023-07-26 | Michael J. Malecek | Disposed 5000 @ 62.33 | View | ||
2023-07-19 | Karin L. Walker | Disposed 5000 @ 69.19 | View | ||
2023-07-12 | Hideki Garren | Disposed 2000 @ 67.51 | View |
Monitoring Prothena Plc's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Prothena |
Prothena Plc's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Prothena Plc's future performance. Based on our forecasts, it is anticipated that Prothena will maintain a workforce of about 170 employees by May 2024.Prothena Plc Management Team Effectiveness
The company has return on total asset (ROA) of (0.1642) % which means that it has lost $0.1642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2485) %, meaning that it created substantial loss on money invested by shareholders. Prothena Plc's management efficiency ratios could be used to measure how well Prothena Plc manages its routine affairs as well as how well it operates its assets and liabilities. As of April 19, 2024, Return On Tangible Assets is expected to decline to -0.21. The current year's Return On Capital Employed is expected to grow to -0.28. At present, Prothena Plc's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 42.3 M, whereas Total Assets are forecasted to decline to about 414.8 M.As of April 19, 2024, Common Stock Shares Outstanding is expected to decline to about 35.1 M. In addition to that, Net Loss is expected to decline to about (110.5 M)
Prothena Plc Workforce Comparison
Prothena plc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 2,957. Prothena Plc holds roughly 173 in number of employees claiming about 6% of equities under Health Care industry.
The company has Profit Margin (PM) of (1.61) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (248.47) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $248.47. Prothena Plc Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Prothena Plc insiders, such as employees or executives, is commonly permitted as long as it does not rely on Prothena Plc's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Prothena Plc insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 5.0 | 10 | 2 | 1,008,000 | 10,000 |
2023-12-01 | 0.3333 | 5 | 15 | 24,000 | 48,000 |
2023-09-01 | 0.3333 | 18 | 54 | 76,000 | 152,000 |
2023-06-01 | 0.4407 | 26 | 59 | 376,333 | 482,666 |
2023-03-01 | 0.5294 | 18 | 34 | 588,834 | 215,668 |
2022-12-01 | 0.2564 | 20 | 78 | 239,500 | 454,280 |
2022-09-01 | 0.3889 | 14 | 36 | 194,662 | 399,246 |
2022-06-01 | 1.5 | 15 | 10 | 1,252,736 | 1,092,736 |
2022-03-01 | 4.0 | 12 | 3 | 1,165,500 | 5,000 |
2021-12-01 | 0.2667 | 8 | 30 | 72,519 | 145,038 |
2021-09-01 | 0.3824 | 13 | 34 | 146,676 | 99,646 |
2021-06-01 | 1.5 | 15 | 10 | 774,250 | 245,000 |
2021-03-01 | 1.4146 | 58 | 41 | 3,310,222 | 1,434,200 |
2020-09-01 | 1.0 | 1 | 1 | 10,000 | 10,000 |
2018-12-01 | 0.5 | 1 | 2 | 35,000 | 130,000 |
2017-12-01 | 0.3333 | 1 | 3 | 3,500 | 7,000 |
2017-09-01 | 0.4348 | 10 | 23 | 54,600 | 109,200 |
2017-06-01 | 0.8462 | 11 | 13 | 200,500 | 123,000 |
2017-03-01 | 0.8235 | 14 | 17 | 374,709 | 97,418 |
2016-12-01 | 0.5294 | 9 | 17 | 172,292 | 84,584 |
2016-09-01 | 0.4615 | 6 | 13 | 79,500 | 59,000 |
2016-06-01 | 1.0 | 12 | 12 | 104,000 | 27,820 |
2016-03-01 | 1.1 | 11 | 10 | 592,125 | 14,250 |
2015-12-01 | 0.3143 | 11 | 35 | 182,916 | 359,166 |
2015-09-01 | 0.3235 | 11 | 34 | 109,916 | 209,833 |
2015-06-01 | 1.1429 | 8 | 7 | 120,125 | 30,250 |
2015-03-01 | 1.6667 | 10 | 6 | 443,625 | 37,250 |
2014-12-01 | 0.5 | 3 | 6 | 7,500 | 15,000 |
2014-09-01 | 1.0 | 2 | 2 | 4,500 | 5,000 |
2014-06-01 | 4.0 | 8 | 2 | 147,356 | 16,000 |
2014-03-01 | 7.0 | 7 | 1 | 402,000 | 3,182,253 |
2013-09-01 | 1.0 | 1 | 1 | 50,000 | 0.00 |
Prothena Plc Notable Stakeholders
A Prothena Plc stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Prothena Plc often face trade-offs trying to please all of them. Prothena Plc's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Prothena Plc's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Dale Schenk | CEO and President and Director | Profile | |
Lars Ekman | Independent Chairman of the Board | Profile | |
Tran Nguyen | CFO | Profile | |
Christopher Henney | Independent Director | Profile | |
Paula Cobb | Director | Profile | |
Shane Cooke | Independent Director | Profile | |
Richard Collier | Independent Director | Profile | |
Dennis Selkoe | Independent Director | Profile | |
Anders Harfstrand | Director | Profile | |
Hideki MD | Chief Officer | Profile | |
Sarah Noonberg | Chief Medical Officer | Profile | |
Tara Nickerson | Chief Business Officer and Secretary | Profile | |
Jennifer Zibuda | Director Communication | Profile | |
Brandon Smith | Chief Officer | Profile | |
Carol Karp | Chief Regulatory Officer | Profile | |
David Ford | Chief Officer | Profile | |
Yvonne Tchrakian | Company Sec | Profile | |
Karin CPA | Chief Controller | Profile | |
Gene Kinney | Chief Scientific Officer and Head of RandD | Profile | |
CPA CPA | Chief Controller | Profile | |
David McNinch | Chief Commercial Officer | Profile | |
Arthur Homan | Chief Legal Officer | Profile | |
Martin Koller | Chief Medical Officer | Profile | |
Wagner Zago | Chief Scientific Officer | Profile | |
Karin Walker | Chief Accounting Officer and Controller | Profile | |
Michael Malecek | Chief Secretary | Profile | |
Mark CFA | Vice Relations | Profile | |
Tran MBA | CFO Officer | Profile |
About Prothena Plc Management Performance
The success or failure of an entity such as Prothena plc often depends on how effective the management is. Prothena Plc management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Prothena management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Prothena management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.20) | (0.21) | |
Return On Capital Employed | (0.30) | (0.28) | |
Return On Assets | (0.21) | (0.22) | |
Return On Equity | (0.26) | (0.25) |
The data published in Prothena Plc's official financial statements usually reflect Prothena Plc's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Prothena plc. For example, before you start analyzing numbers published by Prothena accountants, it's critical to develop an understanding of what Prothena Plc's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Prothena Plc's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Prothena Plc's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Prothena Plc's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Prothena plc. Please utilize our Beneish M Score to check the likelihood of Prothena Plc's management manipulating its earnings.
Prothena Plc Workforce Analysis
Traditionally, organizations such as Prothena Plc use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Prothena Plc within its industry.Prothena Plc Manpower Efficiency
Return on Prothena Plc Manpower
Revenue Per Employee | 528.2K | |
Revenue Per Executive | 3.3M | |
Net Loss Per Employee | 849.9K | |
Net Loss Per Executive | 5.3M | |
Working Capital Per Employee | 3.4M | |
Working Capital Per Executive | 20.8M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Prothena Stock analysis
When running Prothena Plc's price analysis, check to measure Prothena Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prothena Plc is operating at the current time. Most of Prothena Plc's value examination focuses on studying past and present price action to predict the probability of Prothena Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prothena Plc's price. Additionally, you may evaluate how the addition of Prothena Plc to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Prothena Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Revenue Per Share 1.717 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.25) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.